Recent molecular biological investigations have shown that genetic information on the short arm of chromosome 17 is frequently deleted or inactivated in acute myeloid leukaemias and a number of solid tumours. In earlier studies we have found clonal occurrence of a 17p deletion (17p-) in patients with refractory anaemia. In the present study we investigated the time patterns of 17p- and morphological characters of bone marrow cells in 14 myelodysplastic patients with clonal 17p- who have been reinveststigated within 3- to 6-month intervals for 15–56 (median 37) months. We found that the 17p- frequency increases significantly with time. Further, the deletion is positively correlated with bone marrow myeloblast frequencies and negatively with those of maturing granulocytes (myelocytes and later forms). These results suggest that 17p- interferes with and delays granulocyte maturation. Inactivation or deletion of genetic material in 17p in myelodysplastic syndrome, acute myeloid leukaemia, and a wide variety of solid tumours further suggests that genes present on 17p may have a central position in malignant transformation of cells in a number of different tissues.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.